Agreement signed at MediLink headquarters on the 21st... Companies to collaborate on product supply, sales, and marketing

Rose Lab Co., Ltd. CEO Lee Wooseong (left) and MediLink Co., Ltd. CEO Lee Jeonghui pose for a commemorative photo after signing a supply contract for the “Pojeollan Skin Glazer” at MediLink’s headquarters on the 21st. (Photo: Rose Lab)

Rose Lab Co., Ltd. CEO Lee Wooseong (left) and MediLink Co., Ltd. CEO Lee Jeonghui pose for a commemorative photo after signing a supply contract for the “Pojeollan Skin Glazer” at MediLink’s headquarters on the 21st. (Photo: Rose Lab)

View original image

On October 21, Rose Lab Co., Ltd., a company specializing in biomaterials for skin, and MediLink Co., Ltd., a company specializing in sales and marketing for hospitals and clinics, signed a domestic supply agreement for Pojellan Skin Glazer at MediLink's headquarters. Representatives and other officials from both companies attended the signing ceremony.


Under the agreement, MediLink will handle sales and marketing of Pojellan Skin Glazer to hospitals and clinics in Korea. Rose Lab will supply the product and provide academic and marketing materials. The two companies plan to share sales performance and market information and develop joint marketing strategies.


The partnership aims to expand the domestic distribution base by combining Rose Lab's product supply capabilities with MediLink's sales network among hospitals and clinics. The two companies plan to continually share information on demand and supply conditions at medical facilities and further develop their cooperation framework.


Pojellan Skin Glazer is a skincare product designed exclusively for hospitals and clinics that uses liquid PCL (polycaprolactone), a next-generation biomaterial, as its key ingredient. Developed to help manage overall skin condition, including texture, moisture, and elasticity, the product has been presented to medical professionals by Rose Lab, which has built up academic evidence, including through research papers.


MediLink operates a CSO platform for pharmaceutical sales and provides an integrated service that handles everything from searching product commissions and filtering options to submitting performance reports. Alongside ongoing service enhancements, it is expanding into the medical device and cosmetics sectors and working to improve the efficiency of pharmaceutical sales and build a digitally enabled sales environment.


Through this supply agreement, Rose Lab is expected to quickly gain market share in the industry if it can generate synergies with MediLink's systematic sales network.


Rose Lab CEO Lee Woosung said, "Pojellan Skin Glazer is a product for which we have steadily built up academic evidence," adding, "We will work with MediLink, which understands the needs of hospitals and clinics, so that more medical professionals can learn about the product."


MediLink CEO Lee Jeonghee said, "We are pleased to introduce Pojellan Skin Glazer, a product with strong performance and academic evidence, to hospitals and clinics," adding, "We will draw on our on-the-ground sales experience to provide medical professionals with the information and support they need."


Rose Lab plans to expand its domestic distribution channels to hospitals and clinics and strengthen its product supply base following this agreement.



Meanwhile, Rose Lab Co., Ltd. specializes in the research and development of aesthetic medical solutions and functional cosmetics using biocompatible synthetic polymers. It operates the hospital and clinic channel brand Pojellan, the skincare brand Pojellan H, and the home beauty device brand Pojellan Atelier. Its headquarters are located in JCS Tower on Bongeunsa-ro in Gangnam-gu, Seoul.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing